Navigation Links
Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Date:7/22/2009

ly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering. In addition, Trout Capital LLC acted as financial advisor to the Company. The offering was conducted as a public offering pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, New York 10020, or by calling (212) 356-0549.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect the actual future results of the Company and the trading price of securities of the Company. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
2. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
3. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
4. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
6. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
7. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
8. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
9. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
10. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  The full interim results will be presented ... and IGF Society, being held October 15-18, 2014, ...
(Date:9/16/2014)... September 16, 2014 BCC Research ... FOR STEM CELLS , the global market for stem ... by 2018, with a five-year compound annual growth rate ... in the Americas with growth projections of $2.2 billion ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Anesiva,Inc. (Nasdaq: ANSV ) announced today the ... directors. Mr. Janney previously served on Anesiva,s,board from November ... following the merger of Anesiva and AlgoRx Pharmaceuticals., ... of directors,and we are very pleased to welcome him ...
... Inc.,today announced that Edward L. Jacobs, president and ... medical officer,will present an update of the company,s ... Feb. 13, 2008, at the BIO CEO & ... will include information about Semafore,s lead product,candidate, SF1126, ...
... Diagnostic Imaging,International Corp. (OTCBB: DIIG) announced today that ... imaging clinics for acquisition., Following the Company,s ... of profitable operating clinics as well as open ... begun its diligence review on clinics that have,been ...
Cached Biology Technology:Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3Semafore to Present at BIO CEO & Investor Conference 2Diagnostic Imaging - Acquisitions - OTCBB: DIIG 2
(Date:9/16/2014)... Fla. , Sept. 16, 2014  Cross ... identity management solutions, announced today the launch of ... to authenticate the identity of an individual using ... Android-based Verifier Sentry rapidly reads credential documents with ... ID by matching the biometric to a live ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... research has determined that a single group of microorganisms ... B12 production in the oceans, with implications for the ... B12 is an essential molecule required by most life ... relatively small group of microorganisms because it is so ... key role in maintaining the brain and nervous systems, ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... Johnson & Johnson today announced that Axel Ullrich, Ph.D., ... Max Planck Institute of Biochemistry in Germany, whose discoveries ... , is the winner of the 2009 Dr. Paul ... of world-renowned scientists selected Dr. Ullrich, who on September ...
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... time, scientists have shown that chromosomal abnormalities are present ... produced by young, fertile couples. Ms Evelyne Vanneste, a ... the University Fertility Center, Leuven University, Belgium, told the ... Reproduction and Embryology today (Wednesday July 1), that the ...
Cached Biology News:Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Genetically engineered mice yield clues to 'knocking out' cancer 2Chromosomal problems affect nearly all human embryos 2Chromosomal problems affect nearly all human embryos 3
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Storage: Store vial at -20 C prior to opening. ... aliquot contents and freeze at -20 C or below. ... Other Sub-Family: not assigned-Other ...
... Physical form: Essentially sulfate-free, powder ... Preparation Unit Definition: One ... D -fructose 6-phosphate to ... pH 7.4 at 25 C. ...
Biology Products: